,
Pharma Regulatory Services in Kazakhstan – Overview
Kazakhstan’s pharmaceutical market operates within a regulatory framework aligned with the Eurasian Economic Union (EAEU), with national oversight by the Ministry of Health and its expert organizations. Marketing authorizations may be obtained through EAEU Union procedures or via the Kazakhstan National Procedure during the transition period, depending on product status, portfolio strategy, and launch sequencing.
Submissions follow a CTD-aligned dossier format under EAEU requirements and increasingly use electronic submission processes. Sponsors must address Kazakhstan-specific Module 1 administrative requirements, bilingual labeling (Kazakh and Russian), national pharmacovigilance obligations, and post-approval change control. National authorizations must be converted to EAEU Union format in line with evolving regulatory timelines.
Freyr supports sponsors in planning and executing Kazakhstan-specific regulatory strategies, ensuring efficient approvals, compliant market entry, and sustained lifecycle compliance within the EAEU framework.
Authorization pathways in Kazakhstan
- EAEU Union Procedure – Mutual Recognition:
Recognition of an authorization granted in one EAEU Member State across other Member States, including Kazakhstan. - EAEU Union Procedure – Decentralized / Simultaneous:
Coordinated multi-country assessment for first-time Union authorization covering Kazakhstan and other EAEU markets. - Kazakhstan National Procedure:
Single-country authorization for Kazakhstan, with subsequent transition to the EAEU Union format in accordance with regulatory timelines.
Freyr Expertise – Pharma Regulatory Services in Kazakhstan
- Regulatory strategy for Kazakhstan market entry, including selection between EAEU Union and National Procedures, launch sequencing, and transition planning.
- CTD-aligned and EAEU-format dossier authoring, compilation, publishing, and technical validation for initial applications and lifecycle activities.
- National Module 1 preparation for Kazakhstan, including administrative forms, legal documents, fee coordination, and authority correspondence.
- Product information, labeling, and artwork management, including SmPC/PI, PIL, and packaging texts in Kazakh and Russian, aligned with national and EAEU requirements.
- Clinical development and trial regulatory support, including local regulatory submissions, authority interactions, and lifecycle coordination where applicable.
- Pharmacovigilance and safety operations, including local PV contact support, QPPV system setup, PSMF and RMP maintenance, ICSR management, and PSUR/PBRER coordination.
- CMC and quality support, including dossier optimization, ASMF/DMF management, GMP evidence coordination, and manufacturing change support.
- Responses to authority questions, deficiency letters, clock-stop management, and resubmissions.
- Post-approval lifecycle management, including variations, renewals, line extensions, MA transfers, and conversion of national dossiers to EAEU format.
- Serialization and traceability readiness, including SOP alignment and packaging compliance for the Kazakhstan market.
Post-approval and lifecycle management support
Post-authorization obligations in Kazakhstan include ongoing safety reporting, implementation of regulatory changes, labeling maintenance, and timely renewal management under both national and EAEU requirements. Sponsors must also monitor transition milestones to ensure uninterrupted market access as Union rules evolve.
Freyr supports continuous compliance in Kazakhstan by coordinating national and Union lifecycle activities, ensuring regulatory changes are implemented efficiently while maintaining continuity of supply.
Engaging with Freyr enables efficient Kazakhstan market entry, clear navigation of EAEU and national pathways, and sustained regulatory compliance across the product lifecycle.
Ready to scale up your product launch in Kazakhstan